DK0882453T3 - Anvendelse af SPC i kombination med et antiblodplademiddel til behandling af thrombotiske forstyrrelser - Google Patents

Anvendelse af SPC i kombination med et antiblodplademiddel til behandling af thrombotiske forstyrrelser

Info

Publication number
DK0882453T3
DK0882453T3 DK98304327T DK98304327T DK0882453T3 DK 0882453 T3 DK0882453 T3 DK 0882453T3 DK 98304327 T DK98304327 T DK 98304327T DK 98304327 T DK98304327 T DK 98304327T DK 0882453 T3 DK0882453 T3 DK 0882453T3
Authority
DK
Denmark
Prior art keywords
thrombotic disorders
spc
combination
treatment
combination therapy
Prior art date
Application number
DK98304327T
Other languages
English (en)
Inventor
Brian William Grinnell
Joseph Anthony Jakubowski
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0882453T3 publication Critical patent/DK0882453T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Plant Substances (AREA)
DK98304327T 1997-06-05 1998-06-02 Anvendelse af SPC i kombination med et antiblodplademiddel til behandling af thrombotiske forstyrrelser DK0882453T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4862897P 1997-06-05 1997-06-05
EP98304327A EP0882453B1 (en) 1997-06-05 1998-06-02 Use of APC in combination with an antiplatelet agent for treating thrombotic disorders

Publications (1)

Publication Number Publication Date
DK0882453T3 true DK0882453T3 (da) 2005-05-09

Family

ID=21955575

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98304327T DK0882453T3 (da) 1997-06-05 1998-06-02 Anvendelse af SPC i kombination med et antiblodplademiddel til behandling af thrombotiske forstyrrelser

Country Status (23)

Country Link
US (1) US6071514A (da)
EP (1) EP0882453B1 (da)
JP (1) JP2002502421A (da)
KR (1) KR20010013413A (da)
CN (2) CN1265598A (da)
AT (1) ATE286404T1 (da)
AU (1) AU741983B2 (da)
BR (1) BR9809932A (da)
CA (1) CA2293429A1 (da)
DE (1) DE69828462T2 (da)
DK (1) DK0882453T3 (da)
EA (1) EA199901112A1 (da)
ES (1) ES2235291T3 (da)
HU (1) HUP0003964A2 (da)
ID (1) ID23908A (da)
NO (1) NO995776L (da)
PL (1) PL337223A1 (da)
PT (1) PT882453E (da)
SI (1) SI0882453T1 (da)
TR (1) TR199903020T2 (da)
TW (1) TWI228042B (da)
WO (1) WO1998055142A1 (da)
ZA (1) ZA984698B (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000062828A1 (en) 1996-04-30 2000-10-26 Medtronic, Inc. Autologous fibrin sealant and method for making the same
WO1997040864A1 (en) * 1996-04-30 1997-11-06 Medtronic, Inc. Method for making autologous fibrin sealant
US6693075B1 (en) * 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) * 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) * 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6953568B1 (en) 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
WO2001056532A2 (en) * 2000-02-04 2001-08-09 The Scripps Research Institute Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc)
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030056244A1 (en) * 2000-05-02 2003-03-20 Ning Huang Feed additive compositions and methods
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US8906894B1 (en) 2000-07-27 2014-12-09 Thomas N. Thomas Methods for preventing and treating thrombotic disorders
AU2002213192A1 (en) * 2000-10-13 2002-04-22 The Trustees Of Columbia University In The City Of New York A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
US6942880B1 (en) 2001-04-09 2005-09-13 Medtronic, Inc. Autologous platelet gel having beneficial geometric shapes and methods of making the same
US7064130B2 (en) * 2001-04-20 2006-06-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders
CA2462396A1 (en) * 2001-09-19 2003-03-27 Oklahoma Medical Research Foundation Treatment of sepsis with tafi
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
ATE502642T1 (de) * 2001-10-05 2011-04-15 Zalicus Inc Kombinationen für die behandlung von immun- entzündlichen erkrankungen
EP1587838B1 (en) 2003-01-10 2015-04-15 Ablynx N.V. Therapeutic polypeptides, homologues thereof, fragments thereof and their use in modulating platelet-mediated aggregation
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
JP2008507561A (ja) * 2004-07-23 2008-03-13 ザ ユニバーシティ オブ ロチェスター 活性化プロテインｃによる、脳内のプラスミノゲン活性化因子の不都合な作用の阻害
SI2007362T1 (sl) * 2006-04-04 2018-12-31 Kg Acquisition Llc Peroralne odmerne oblike, ki vključujejo antitrombocitno sredstvo in inhibitor kisline
US9096839B2 (en) * 2006-04-26 2015-08-04 Arteriocyte Medical Systems, Inc. Compositions and methods of preparation thereof
CA2652773A1 (en) * 2006-05-22 2007-12-06 Combinatorx, Incorporated Methods and compositions for the treatment of diseases or conditions associated with increased c-reactive protein, interleukin-6, or interferon-gamma levels
CN101686681B (zh) 2007-04-27 2015-04-01 锡德克斯药物公司 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法
CA2737131A1 (en) * 2007-09-19 2009-03-26 Zalicus Inc. Therapeutic regimens for the treatment of immunoinflammatory disorders
KR20100121601A (ko) * 2007-12-17 2010-11-18 콤비네이토릭스, 인코포레이티드 면역염증성 질환의 치료를 위한 치료요법
DE102007063234A1 (de) * 2007-12-31 2009-07-02 Nowak, Attila, Dipl.-Ing. Schnellere Speicherorganisation
US20100280594A1 (en) * 2009-05-01 2010-11-04 Medi-Solve, Llc Antithrombotic Neurovascular Device Containing a Glycoprotein IIB/IIIA Receptor Inhibitor for The Treatment of Brain Aneurysms and/or Acute Ischemic Stroke, and Methods Related Thereto
WO2010132711A1 (en) 2009-05-13 2010-11-18 Cydex Pharmaceuticals, Inc. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
CN108159399B (zh) * 2017-12-29 2020-07-24 华中科技大学同济医学院附属同济医院 一种凝血蛋白酶aPC在防治糖尿病心肌病药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) * 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
FR2671973A1 (fr) * 1991-01-25 1992-07-31 Fondation Nale Transfusion San Utilisation de la proteine c activee comme agent anti-agregant plaquettaire.
WO1993009807A1 (en) * 1991-11-18 1993-05-27 The Scripps Research Institute Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels
JPH05271098A (ja) * 1992-03-26 1993-10-19 Teijin Ltd 活性化プロテインｃを有効成分とする抗血小板剤
MY110664A (en) * 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
IL110172A (en) * 1993-07-22 2001-10-31 Lilly Co Eli Bicyclic compounds and pharmaceutical compositions containing them
WO1997020043A1 (en) * 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals

Also Published As

Publication number Publication date
EA199901112A1 (ru) 2000-06-26
ZA984698B (en) 2000-02-01
EP0882453A3 (en) 2001-04-04
JP2002502421A (ja) 2002-01-22
ID23908A (id) 2000-05-25
CN1347734A (zh) 2002-05-08
BR9809932A (pt) 2000-08-01
WO1998055142A1 (en) 1998-12-10
AU7710098A (en) 1998-12-21
TR199903020T2 (xx) 2000-08-21
AU741983B2 (en) 2001-12-13
ATE286404T1 (de) 2005-01-15
TWI228042B (en) 2005-02-21
NO995776L (no) 2000-01-26
DE69828462T2 (de) 2005-12-15
SI0882453T1 (en) 2005-06-30
CA2293429A1 (en) 1998-12-10
CN1265598A (zh) 2000-09-06
DE69828462D1 (de) 2005-02-10
PT882453E (pt) 2005-04-29
EP0882453A2 (en) 1998-12-09
NO995776D0 (no) 1999-11-25
US6071514A (en) 2000-06-06
EP0882453B1 (en) 2005-01-05
PL337223A1 (en) 2000-08-14
ES2235291T3 (es) 2005-07-01
KR20010013413A (ko) 2001-02-26
HUP0003964A2 (en) 2001-03-28

Similar Documents

Publication Publication Date Title
DK0882453T3 (da) Anvendelse af SPC i kombination med et antiblodplademiddel til behandling af thrombotiske forstyrrelser
BR0212039B1 (pt) dispositivo terapêutico a laser de nìvel baixo.
PL350291A1 (en) Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
EA200300953A1 (ru) Терапевтические комбинации для применения при сердечно-сосудистых и воспалительных заболеваниях
ATE177949T1 (de) Kombinationstherapie zur prophylaxe und/oder behandlung benigner prostatahyperplasie
ATE218854T1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase
DK0627221T3 (da) Substans P antagonister til behandling af emesis
PT1140181E (pt) Terapia de combinacao de radiacao e um inibidor de cox-2 para o tratamento da neoplasia
DE69841041D1 (de) Stent beschichtet mit dna
DE60313603D1 (de) Pharmazeutische kombination zur behandlung von benigner prostatahyperplasie oder zur langzeitvorbeugung von akuter harnzurückhaltung
DE60037032D1 (de) Anwendung von pdt zur inhibierung von hyperplasie der intima
NO962406L (no) Farmasöytisk formulering for profylakse henholdsvis for behandling av en forgiftning ved fosfororganiske kolinesterasehemmere
DK1339417T3 (da) Præparat til behandling af åbne, flade sår
ATE141789T1 (de) Zusammensetzung enthaltend dibucaine- hydrochlorid, ein salicylat, calciumbromid und ein antiphlogistisches steroid zur schmerzbekämpfung
DK664188D0 (da) Butylhydroxyanisoler til behandling af retrovirale sygdomme
ATE314073T1 (de) Kombination von aktiva mit alfuzosin und apomorphin
YU40098A (sh) Upotreba olanzapina za dobijanje leka
ITNA20020028A1 (it) Nuove applicazioni terapeutiche per prevenire l'insuccesso dell'impianto di endoprotesi, o stents, e l'occlusione dei graft venosi mediante
ITVR920053V0 (it) Vaporizzatore comprendente organi per il dosaggio, la diffusione e la vaporizzazione dell'acqua applicabile preferibilmente su forni modula-ri o similari